AI assistant
Sending…
Athira Pharma, Inc. — Director's Dealing 2021
Jun 9, 2021
35038_dirs_2021-06-09_6732a934-e012-4361-996c-f2ab6586ed79.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2021-06-08
Reporting Person: CHURCH KEVIN (Vice President of Discovery)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-08 | Common Stock | M | 3152 | $1.04 | Acquired | 44133 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-08 | Stock Option (Right to Buy) | $1.04 | M | 3152 | Disposed | 2026-08-30 | Common Stock (3152) | Direct |
Footnotes
F1: The shares subject to the option fully vested on September 1, 2016.
More from Athira Pharma, Inc.
Annual Report
2026
May 11
Capital/Financing Update
2026
Apr 1
Regulatory Filings
2026
Mar 31
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Board/Management Information
2026
Mar 19
Proxy Solicitation & Information Statement
2026
Feb 23
Major Shareholding Notification
2026
Feb 6
Capital/Financing Update
2026
Jan 20
Capital/Financing Update
2026
Jan 20